AstraZeneca COVID-19 vaccine and Guillain- Barré Syndrome in Tasmania: A causal link?

The emergence of the coronavirus 2019 (COVID-19) pandemic has presented an unprecedented global challenge. Vaccines against COVID have been developed to date. Covid-19 has been linked with the development of Guillain-Barre Syndrome (GBS), a rare immune-mediated demyelinating neuropathy. We report th...

Descripción completa

Detalles Bibliográficos
Autores principales: Oo, Wai M., Giri, Pradeep, de Souza, Aaron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447540/
https://www.ncbi.nlm.nih.gov/pubmed/34560365
http://dx.doi.org/10.1016/j.jneuroim.2021.577719
_version_ 1784569036750716928
author Oo, Wai M.
Giri, Pradeep
de Souza, Aaron
author_facet Oo, Wai M.
Giri, Pradeep
de Souza, Aaron
author_sort Oo, Wai M.
collection PubMed
description The emergence of the coronavirus 2019 (COVID-19) pandemic has presented an unprecedented global challenge. Vaccines against COVID have been developed to date. Covid-19 has been linked with the development of Guillain-Barre Syndrome (GBS), a rare immune-mediated demyelinating neuropathy. We report three cases of Guillain-Barre Syndrome and one case of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), presenting to a Tasmanian hospital, and review 15 other reported cases and discuss likely immunopathology. Nearly all reported cases of post-COVID-19 vacciation inflammatory demyelinating polyneuropathy are linked to AstraZeneca vaccination and a variant with bifacial weakness is the most reported form of GBS globally.
format Online
Article
Text
id pubmed-8447540
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-84475402021-09-17 AstraZeneca COVID-19 vaccine and Guillain- Barré Syndrome in Tasmania: A causal link? Oo, Wai M. Giri, Pradeep de Souza, Aaron J Neuroimmunol Review Article The emergence of the coronavirus 2019 (COVID-19) pandemic has presented an unprecedented global challenge. Vaccines against COVID have been developed to date. Covid-19 has been linked with the development of Guillain-Barre Syndrome (GBS), a rare immune-mediated demyelinating neuropathy. We report three cases of Guillain-Barre Syndrome and one case of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), presenting to a Tasmanian hospital, and review 15 other reported cases and discuss likely immunopathology. Nearly all reported cases of post-COVID-19 vacciation inflammatory demyelinating polyneuropathy are linked to AstraZeneca vaccination and a variant with bifacial weakness is the most reported form of GBS globally. Published by Elsevier B.V. 2021-11-15 2021-09-17 /pmc/articles/PMC8447540/ /pubmed/34560365 http://dx.doi.org/10.1016/j.jneuroim.2021.577719 Text en Crown Copyright © 2021 Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review Article
Oo, Wai M.
Giri, Pradeep
de Souza, Aaron
AstraZeneca COVID-19 vaccine and Guillain- Barré Syndrome in Tasmania: A causal link?
title AstraZeneca COVID-19 vaccine and Guillain- Barré Syndrome in Tasmania: A causal link?
title_full AstraZeneca COVID-19 vaccine and Guillain- Barré Syndrome in Tasmania: A causal link?
title_fullStr AstraZeneca COVID-19 vaccine and Guillain- Barré Syndrome in Tasmania: A causal link?
title_full_unstemmed AstraZeneca COVID-19 vaccine and Guillain- Barré Syndrome in Tasmania: A causal link?
title_short AstraZeneca COVID-19 vaccine and Guillain- Barré Syndrome in Tasmania: A causal link?
title_sort astrazeneca covid-19 vaccine and guillain- barré syndrome in tasmania: a causal link?
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447540/
https://www.ncbi.nlm.nih.gov/pubmed/34560365
http://dx.doi.org/10.1016/j.jneuroim.2021.577719
work_keys_str_mv AT oowaim astrazenecacovid19vaccineandguillainbarresyndromeintasmaniaacausallink
AT giripradeep astrazenecacovid19vaccineandguillainbarresyndromeintasmaniaacausallink
AT desouzaaaron astrazenecacovid19vaccineandguillainbarresyndromeintasmaniaacausallink

Ejemplares similares